RVTY · 8-K · 20260804PR000022

Segment Revenue Trends

REVVITY, INC. · 2026-08-04 · Importance 54 · Surprise 40 · From source text

Diagnostics revenue increased to $371 million from $354 million, representing 12% pro forma growth and 11% pro forma organic growth year over year. Life Sciences revenue declined to $359 million from $366 million, with pro forma revenue down 2% and pro forma organic revenue down 3%. For the first six months, Diagnostics pro forma organic revenue grew 10%, while Life Sciences pro forma organic revenue was flat.

Key facts

• Life Sciences second quarter 2026 revenue: $359 million; compared to $366 million in the same period a year ago. source
• Life Sciences pro forma revenue decreased 2% and pro forma organic revenue decreased 3% year-over-year for the quarter. source
• Diagnostics second quarter 2026 revenue: $371 million; compared to $354 million in the same period a year ago. source
• Diagnostics pro forma revenue increased 12% and pro forma organic revenue increased 11% year-over-year for the quarter. source
• Diagnostics pro forma organic revenue growth for six months ended July 5, 2026: 10% (pro forma revenue growth 12% less foreign exchange 2% and acquisitions 0%). source
• Three months ended July 5, 2026 Life Sciences segment revenue (GAAP): $358,699 (thousands). source
• Three months ended July 5, 2026 Diagnostics segment revenue (GAAP): $370,989 (thousands). source
• Life Sciences pro forma organic revenue growth for six months ended July 5, 2026: 0% (pro forma revenue growth 2% less foreign exchange 1% and acquisitions 1%). source

Impact estimates